BrandWikiReturn

Plexxikon

Plexxikon is an American drug discovery company based in South San Francisco, California. It was co-founded in 2001 by Joseph Schlessinger of Yale University, and Sung-Hou Kim of the University of California, Berkeley.

It uses a proprietary structural biology-based platform called Scaffold-Based Drug Discovery to build a pipeline of products in multiple therapeutic areas. This discovery process integrates multiple technologies, including structural screening as one key component, that it hopes will give a significant competitive advantage over other approaches.[1]

In April 2011, Plexxikon was acquired by the Japanese pharmaceutical company Daiichi Sankyo for $805 million and an additional $130 million in potential milestone payments.[2][3][4]

Daiichi Sankyo announced the shutdown of Plexxikon in 2022.[5]

Drug pipeline

  • Vemurafenib (Zelboraf) and pexidartinib (Turalio) are two FDA approved drugs developed by Plexxikon
  • Plexxikon is collaborating with Wyeth Pharmaceuticals on several products for use in type II diabetes and other metabolic disorders.[6] The most advanced of these agents is indeglitazar (PLX204), which is currently in Phase II clinical trials for type 2 diabetes.[7]
  • PLX7486 is a CSF1R antagonist and pan-TRK inhibitor in clinical trials for advanced solid tumors.[8][9]

See also

References

  1. AI Drug Discovery: Key Trends and Developments in Pharmaceutical Industry www.biopharmatrend.com, retrieved 2023-09-11^
  2. Daiichi Sankyo to Acquire Plexxikon Plexxikon, 2011-02-28^
  3. Plexxikon acquired by Daiichi Sankyo Haberman Associates, 2011-03-03, retrieved 2020-08-06^
  4. Daiichi Sankyo, Inc. Completes Plexxikon Inc. Acquisition BioSpace, retrieved 2020-08-06^
  5. Madeline Wells. South SF company bought for $800 million is being shut down SFGATE, 2022-01-12^
  6. Wyeth, Plexxikon tie up to develop novel diabetes & metabolic disorders treatment 28 October 2004^
  7. Study Evaluating PPM-204 In Subjects With Type 2 Diabetes - Full Text View - ClinicalTrials.gov Clinical Trials, 18 December 2007, retrieved 2020-10-09^
  8. Fms/Trk tyrosine kinase inhibitor PLX7486 NCI Drug Dictionary, National Cancer Institute^
  9. Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors ClinicalTrials.gov, 2018-08-02^